Skip to main content
Cellectis logo

Cellectis — Investor Relations & Filings

Ticker · ALCLS ISIN · FR0010425595 LEI · 5493000KKX5VQ37Q2W83 PA Manufacturing
Open in API
Filings indexed 1,309 across all filing types
Latest filing 2026-05-06 Declaration of Voting R…
Country FR France
Listing PA ALCLS

About Cellectis

https://cellectis.com/en

Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.

Recent filings

Filing Released Lang Actions
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2026-05-06 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2026-05-06 English
Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026
Regulatory Filings
2026-05-04 French
Cellectis to Report First Quarter Financial Results on May 11, 2026
Regulatory Filings
2026-05-04 English
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Regulatory Filings Classification · 20% confidence The document is a corporate press release announcing a scientific poster presentation at a gene therapy conference. It contains no financial results, no regulatory vote or capital change, no dividend or board change notice, no shareholder transaction, and no formal report attached or published. It is not an earnings release or investor presentation deck. It is effectively a general corporate announcement not covered by any specific category, so it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-27 English
Cellectis présente sa plateforme d’édition épigénétique pour éteindre des gènes sans modifier l’ADN, lors du congrès annuel de l’ASGCT
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing a scientific poster presentation at a conference (ASGCT). It does not contain financial results, voting details, management changes, or formal regulatory report content. It is not an investor presentation deck, dividend notice, or other specifc report. Therefore, it falls into the fallback category of general regulatory or corporate announcements.
2026-04-27 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.